Improving the Prudent Use of Biosimilars in Patients with hematologic malignancies or in Supportive Care in Nigeria: A Regional Educational Program for health care professionals | Sponsor: Pfizer Plc

Status: Project Completed and Final report submitted to Pfizer Plc

Sponsor: Pfizer Plc

Centre for Initiative and Development (CFID) in conjunction with Nigerian Medical Association (NMA), with a Medical Educational Grant from Pfizer, conducted series of educational programs for Multi-Disciplinary Health Care Workers in north-east Nigeria.

The training were independently developed and delivered by CFID and all partners. Pfizer Plc, had no involvement in the educational project, selection of participants nor implementing any activities.

CFID had targeted to provide training in 6 tertiary hospitals namely:

  • Abubakar Tafawa Balewa University Teaching Hospital, (ATBUTH), Bauchi, Bauchi state
  • Benue State University Teaching Hospital (BSUTH) Makurdi, Benue
  • Federal Teaching Hospital, Gombe, Gombe State
  • Federal Medical Centre, Jalingo, Taraba State

Project methodology: The following approach was adopted for the health care workers educational program:

  • Webinars on “Guidelines on Nigeria’s regulatory framework governing the approval of biosimilar drugs”.

This was an educational program aimed at increasing a broad-based level of knowledge and information on Biosimilars and their use in Nigeria.

  • Face to face Live meetings in all target hospitals across the two regions in Nigeria:

CFID worked with the management of each respective hospital and the Nigerian Medical Association to mobilize multi-disciplinary health care professionals in each hospital.  Participants were invited to participate in the four-five hour weekly event for two weeks, to ensure the modules were covered. These sessions were held in each target hospital and were facilitated by expert Oncologists, Physicians, and Pharmacists through didactic presentations, group workshops, brainstorming sessions. The aim of the training was to improve the health care worker’s knowledge on the prudent use of Biosimilars in Patients with Hematologic malignancies in supportive care in Nigeria. 1071 Healthcare professionals participated in the training even with the COVID-19 restrictions which limited the numbers of persons allowed in public gatherings per time.

  • The Training through power point presentation of a comprehensive module, robust question and answer sessions as well as the administration of the Pre & Post testing evaluation mechanism revealed knowledge was imparted to the participants. More follow –up trainings are advocated for to solidify the gains of the inaugural training as well as to share recent information and data available on Biosimilars.
  • CFID surpassed the expected number of participants, from the 950 projected in the proposal to 1,071 health care professionals trained across all target hospitals
  • COVID-19 protocols were strictly adhered to at all venues of trainings

Participants’ consent was obtained to share these pictures of project activities.

About Administrator

Check Also

CFID Taraba in collaboration with NMA and NCS

CFID Taraba in collaboration with NMA and NCS implemented a project sponsored by CFID in …

Leave a Reply

Your email address will not be published.